Cornerstone Pharmaceuticals
Cranbury,, US · 19 employees on LinkedIn
Find your way into Cornerstone Pharmaceuticals
133 people in our graph share verified history with the Cornerstone Pharmaceuticals team — schools, employers, funds. One of them is your warm intro.
Michael Eisenbergunlockedknows David A. Polinsky · together at Yeshiva University (overlapped)
×9knows the team · via Fordham University School of Law
×2knows the team · via Yeshiva University
Cornerstone Pharmaceuticals develops anti-metabolic cancer therapies and is testing its lead drug candidate, CPI-613 (devimistat), in combinations using preclinical cancer models.
Founders & leadership
RS
Robert ShorrFounder
DA
David A. PolinskyinCo-Founder, President, and General Counsel2002–2018David A. Polinsky previously served as Chief Financial Officer at Rafael Holdings, a publicly-traded biotechnology company, where he oversaw finance, legal, and corporate strategy. He holds a Juris Doctorate from Fordham University School of Law and has over 25 years of experience in senior management at private and public companies, including co-founding and leading multiple startups through various development stages.
RR
Robert RodriguezinExecutive
CH
Clifford H StraubExecutive
Board
PS
Patrick S. WilmerdingBoard director
HJ
Howard JonasBoard director
JA
Joseph A. SternBoard director
AD
Aaron DrillickBoard director
SF
Sim FassBoard director
HG
Herman Gilbert PolinskyBoard director
Reported raises · per SEC filings
Form D private placements$3.3M disclosed across 1 round · 2014
▶$3.3MraisedMar 2014 · 1 investors · PharmaceuticalsRule 506(b)
▶$3.3MraisedMar 2014 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Patrick S. WilmerdingDirector
- Howard JonasDirector
- Joseph A. SternDirector
- Robert ShorrExecutive Officer, Director
- Aaron DrillickDirector
- Sim FassDirector
- David A. PolinskyExecutive Officer, Director
- Herman Gilbert PolinskyDirector
- Robert RodriguezExecutive Officer, Director
- Clifford H StraubExecutive Officer
- Offering amount
- $7.5M
- Amount sold
- $3.3M
- Proceeds to insiders
- $1.9M
- First sale
- Feb 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Cornerstone Pharmaceuticals do?
- Cornerstone Pharmaceuticals develops anti-metabolic cancer therapies and is testing its lead drug candidate, CPI-613 (devimistat), in combinations using preclinical cancer models.
- Who founded Cornerstone Pharmaceuticals?
- Cornerstone Pharmaceuticals was founded by Robert Shorr.
- How much funding has Cornerstone Pharmaceuticals raised?
- Cornerstone Pharmaceuticals has disclosed $3.3M raised across 1 round.
- Where is Cornerstone Pharmaceuticals headquartered?
- Cornerstone Pharmaceuticals is headquartered in Cranbury,, US.